Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with duchenne muscular dystrophy: An observational multicenter trial

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Seferian, Andreea Mihaela ^a   Moraux, Amélie ^a   Annoussamy, Mélanie ^a   Canal, Aurélie ^a   Decostre, Valérie ^a   Diebate, Oumar ^a   Le Moing, Anne Gaëlle ^a,b   Gidaro, Teresa ^a   Deconinck, Nicolas ^c   Van Parys, Frauke ^c   Vereecke, Wendy ^c   Wittevrongel, Sylvia ^c   Mayer, Michèle ^d   Maincent, Kim ^d   Desguerre, Isabelle ^d   Thémar Noël, Christine ^a   Cuisset, Jean Marie ^e   Tiffreau, Vincent ^e   Denis, Severine ^f   Jousten, Virginie ^f   Quijano Roy, Susana ^g   Voit, Thomas ^a,h   Hogrel, Jean Yves ^a   Servais, Laurent ^f   more..

^a Institute of Myology   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c Department of Pediatrics   (Belgium)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f Centre Hospitalier Regional de La Citadelle   (Belgium)

^g LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^h Sorbonne Université   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARM MOVEMENT; ARTICLE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; FORCED VITAL CAPACITY; GRIP STRENGTH; HAND FUNCTION; HUMAN; LIMITED MOBILITY; MAJOR CLINICAL STUDY; MOBILIZATION; MOTOR PERFORMANCE; MULTICENTER STUDY; MUSCLE STRENGTH; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PINCH STRENGTH; RELIABILITY; SCHOOL CHILD; ARM; CLINICAL TRIAL; CONVALESCENCE; DRUG EFFECTS; FEMALE; FOLLOW UP; MALE; MUSCULAR DYSTROPHY, DUCHENNE; PATHOPHYSIOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MUSCLE STRENGTH; MUSCULAR DYSTROPHY, DUCHENNE; RECOVERY OF FUNCTION; UPPER EXTREMITY; YOUNG ADULT;

EID: 84922311710     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113999     Document Type: Article

References (36)

1. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, et al. (2010) Diagnosis andmanagement of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 9: 177-189. doi: 10.1016/S1474-4422(09)70272-8 PMID: 19945914
2. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, et al. (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9: 77-93. doi: 10.1016/S1474-4422(09)70272-8 PMID: 19945913
3. Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, et al. (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378: 595-605. doi: 10.1016/S0140-6736(11)60756-3 PMID: 21784508
4. Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, et al. (2011) Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 364: 1513-1522. doi: 10.1056/ NEJMoa1011367 PMID: 21428760
5. Mendell J, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, et al. (2013) Eteplirsen for the treatment of duchenne muscular dystrophy. Ann Neurol.
6. Mercuri E, Muntoni F (2013) Muscular dystrophies. Lancet 381: 845-860. doi: 10.1016/S0140-6736 (12)61897-2 PMID: 23465426
7. McDonald CM, Henricson EK, Abresch RT, Florence JM, Eagle M, et al. (2013) The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: Longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve.
8. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, et al. (2010) The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 41: 500-510. doi: 10.1002/ mus.21544 PMID: 19941337
9. Mercuri E,Mayhew A, Muntoni F, Messina S, Straub V, et al. (2008) Towards harmonisation of outcomemeasures for DMD and SMA within TREAT-NMD; report of three expert workshops: TREAT-NMD/ENMC workshop on outcomemeasures, 12th-13thMay 2007, Naarden, The Netherlands; TREAT-NMD workshop on outcomemeasures in experimental trials for DMD, 30th June-1st July 2007, Naarden, The Netherlands; conjoint Institute ofMyology TREAT-NMDmeeting on physical activitymonitoring in neuromuscular disorders, 11th July 2007, Paris, France. Neuromuscul Disord 18: 894-903. PMID: 18818076
10. Mercuri E, McDonald C, Mayhew A, Florence J, Mazzone E, et al. (2012) International workshop on assessment of upper limb function in Duchenne Muscular Dystrophy: Rome, 15-16 February 2012. Neuromuscul Disord 22: 1025-1028. doi: 10.1016/j.nmd.2012.06.006 PMID: 22795657
11. Mazzone ES, Vasco G, Palermo C, Bianco F, Galluccio C, et al. (2012) A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy. Dev Med Child Neurol 54: 879-885. doi: 10.1111/j.1469-8749.2012.04345.x PMID: 22713125
12. Mayhew A, Mazzone ES, Eagle M, Duong T, Ash M, et al. (2013) Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy. Dev Med Child Neurol.
13. Pane M, Mazzone ES, Fanelli L, De Sanctis R, Bianco F, et al. (2013) Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy. Neuromuscul Disord.
14. Kurillo G, Han JJ, Abresch RT, Nicorici A, Yan P, et al. (2012) Development and application of stereo camera-based upper extremity workspace evaluation in patients with neuromuscular diseases. PLoS One 7: e45341. doi: 10.1371/journal.pone.0045341 PMID: 23028947
15. Kurillo G, Han JJ, Nicorici A, Johnson LB, Abresch RT, et al. (2013) Upper extremity reachable workspace evaluation in DMD using Kinect. Neuromuscular Disorders 23: 749-750. doi: 10.1016/j.nmd.2013.06.409
16. Lowes LP, Alfano LN, Yetter BA, Worthen-Chaudhari L, Hinchman W, et al. (2013) Proof of concept of the ability of the kinect to quantify upper extremity function in dystrophinopathy. PLoS Curr 5.
17. Mayhew JE, Florence JM, Mayhew TP, Henricson EK, Leshner RT, et al. (2007) Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy. Muscle Nerve 35: 36-42. doi: 10.1002/mus.20654 PMID: 16969838
18. Stuberg WA, Metcalf WK (1988) Reliability of quantitative muscle testing in healthy children and in children with Duchenne muscular dystrophy using a hand-held dynamometer. Phys Ther 68: 977-982. PMID: 3375322
19. Bartels B, Pangalila RF, Bergen MP, Cobben NA, Stam HJ, et al. (2011) Upper limb function in adults with Duchenne muscular dystrophy. J Rehabil Med 43: 770-775. doi: 10.2340/16501977-0841 PMID: 21826385
20. Mazzone E, Bianco F, Martinelli D, Glanzman AM, Messina S, et al. (2011) Assessing upper limb function in nonambulant SMA patients: development of a new module. Neuromuscul Disord 21: 406-412. doi: 10.1016/j.nmd.2011.02.014 PMID: 21421316
21. Wagner MB, Vignos PJ Jr, Carlozzi C, Hull AL (1993) Assessment of hand function in Duchenne muscular dystrophy. Arch Phys Med Rehabil 74: 801-804. doi: 10.1016/0003-9993(93)90004-T PMID: 8347064
22. Henricson EK, Abresch RT, Cnaan A, Hu F, Duong T, et al. (2013) The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle Nerve 48: 55-67. doi: 10.1002/mus.23808 PMID: 23649481
23. Scott OM, Hyde SA, Goddard C, Dubowitz V (1982) Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy. Muscle Nerve 5: 291-301. doi: 10.1002/mus. 880050405 PMID: 7099196
24. Buyse GM, Goemans N, van den Hauwe M, Thijs D, de Groot IJ, et al. (2011) Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial. Neuromuscul Disord 21: 396-405. doi: 10.1016/j.nmd.2011.02.016 PMID: 21435876
25. Lerario A, Bonfiglio S, Sormani M, Tettamanti A, Marktel S, et al. (2012) Quantitative muscle strength assessment in duchenne muscular dystrophy: longitudinal study and correlation with functional measures. BMC Neurol 12: 91. doi: 10.1186/1471-2377-12-91 PMID: 22974002
26. Servais L, Deconinck N, Moraux A, Benali M, Canal A, et al. (2013) Innovativemethods to assess upper limb strength and function in non-ambulant Duchenne patients. Neuromuscul Disord 23: 139-148. doi: 10. 1016/j.nmd.2012.10.022 PMID: 23219352
27. Daoud F, Angeard N, Demerre B, Martie I, Benyaou R, et al. (2009) Analysis of Dp71 contribution in the severity of mental retardation through comparison of Duchenne and Becker patients differing by mutation consequences on Dp71 expression. Hum Mol Genet 18: 3779-3794. doi: 10.1093/hmg/ddp320 PMID: 19602481
28. - (2002) ATS statement: guidelines for the six-minute walk test. AmJ Respir Crit CareMed 166: 111-117. doi: 10.1164/ajrccm.166.1.at1102 PMID: 12091180
29. Chow S-C, Shao J, Wang H (2008) Sample size calculations in clinical research. Boca Raton: Chapman & Hall/CRC. xiv, 465 p. p.
30. Desguerre I, Christov C, Mayer M, Zeller R, Becane HM, et al. (2009) Clinical heterogeneity of duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up. PLoS One 4: e4347. doi: 10.1371/journal.pone.0004347 PMID: 19194511
31. Dooley JM, Gordon KE, MacSween JM (2010) Impact of steroids on surgical experiences of patients with duchenne muscular dystrophy. Pediatr Neurol 43: 173-176. doi: 10.1016/j.pediatrneurol.2010.04. 013 PMID: 20691938
32. Roberto R, Fritz A, Hagar Y, Boice B, Skalsky A, et al. (2011) The natural history of cardiac and pulmonary function decline in patients with duchenne muscular dystrophy. Spine (Phila Pa 1976) 36: E1009-1017. doi: 10.1097/BRS.0b013e3181fea1ed
33. Vuillerot C, Payan C, Girardot F, Fermanian J, Iwaz J, et al. (2012) Responsiveness of the motor function measure in neuromuscular diseases. Arch Phys Med Rehabil 93: 2251-2256 e2251. doi: 10.1016/ j.apmr.2012.05.025 PMID: 22705238
34. Pane M, Mazzone ES, Sormani MP, Messina S, Vita GL, et al. (2014) 6 minute walk test in duchenne MD patients with different mutations: 12 month changes. PLoS One 9: e83400. doi: 10.1371/journal. pone.0083400 PMID: 24421885
35. Mattar FL, Sobreira C (2008) Hand weakness in Duchenne muscular dystrophy and its relation to physical disability. Neuromuscul Disord 18: 193-198. doi: 10.1016/j.nmd.2007.11.004 PMID: 18207403
36. Humbertclaude V, Hamroun D, Bezzou K, Berard C, Boespflug-Tanguy O, et al. (2012) Motor and respiratory heterogeneity in Duchenne patients: implication for clinical trials. Eur J Paediatr Neurol 16: 149-160. doi: 10.1016/j.ejpn.2011.07.001 PMID: 21920787